Piscataway, NJ, April 9, 2025 – Camber Pharmaceuticals is excited to announce the addition of Mycophenolate Mofetil Capsules, USP to their portfolio.
Mycophenolate Mofetil Capsules, USP are indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.
Mycophenolate Mofetil Capsules, USP 250 mg are available in 100 and 500 count bottles.
To find out more information on Mycophenolate Mofetil Capsules, USP, please visit: www.camberpharma.com/mycophenolatecapsules
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dose manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers and improving quality of life through cost-effective medications.
